Digitization-Centric Strategy to Drive the CAR T-
Cell Therapy Market
According to a recent study by Persistence Market Research, the global CAR T-cell
therapy market is anticipated to experience high growth over the coming years. The
market is expected to grow from US$ 1.2 Bn in 2020 to over US$ 2.8 Bn by 2031, which
reflects a CAGR of around 5.6% for the next ten years.
Key players in the CAR T-cell therapy space are focusing on acquisitions and collaborations
with other players of the market to strengthen their position by offering a wide range of
For instance, in December 2017, Gilead Science acquired Cell Design Labs Inc., which is a
privately held company of biotherapeutics that discovers and develops cell-based therapies.
This acquisition benefits Gilead through gaining novel technology platforms that will its
boost R&D efforts in cellular therapy.
Get Sample Copy of this
Also, increasing number of clinical trials in the field of life sciences and CAR T-cells will
benefit manufacturers and researchers in developing innovative cancer therapy. With a
large extent of studies taking place around CAR T-cell therapy, it is anticipated to enhance
product availability in the market over the coming years.
For instance, the experiment on AntiCD19 Chimeric Antigen Receptor T Cells for the
treatment of relapsed or refractory Non-Hodgkin lymphoma by Benjamin Tomlinson is
undergoing and is currently in phase I clinical trial.
Another study by Janssen Research & Development, LLC of a chimeric antigen receptor T
Cell (CAR-T) therapy for myeloma is in phase 2 clinical trial.
Furthermore, a study on the safety and efficacy of ALLO-605 in patients with
relapsed/refractory multiple myeloma by Allogene Therapeutics is currently in phase 2.
All these factors will drive demand for CAR T-cell therapy during the forecast period (2021
Gilead Sciences Inc.